The nicotinic acetylcholine receptor partial agonist varenicline and the treatment of drug dependence: A review

被引：46
|
作者：
Crunelle, Cleo L. [1 ,2 ,3 ]
Miller, Michelle L. [1 ,2 ,3 ]
Booij, Jan [3 ]
van den Brink, Wim [1 ,2 ]
机构：
[1] Univ Amsterdam, Acad Med Ctr, Dept Psychiat, NL-1070 AW Amsterdam, Netherlands
[2] Univ Amsterdam, Acad Med Ctr, Amsterdam Inst Addict Res, NL-1070 AW Amsterdam, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Nucl Med, NL-1070 AW Amsterdam, Netherlands
来源：
EUROPEAN NEUROPSYCHOPHARMACOLOGY | 2010年 / 20卷 / 02期
关键词：
Varenicline; Atpha4 beta2 nicotinic acetylcholine receptor; Partial agonist; Addiction; Drug dependence; Relapse prevention; VENTRAL TEGMENTAL AREA; ACCUMBAL DOPAMINE OVERFLOW; VOLUNTARY ETHANOL INTAKE; SMOKING-CESSATION; MOLECULAR-MECHANISMS; MESOLIMBIC DOPAMINE; REINFORCING PROPERTIES; SYNAPTIC-TRANSMISSION; INDUCED HYPERACTIVITY; NUCLEUS-ACCUMBENS;
D O I：
10.1016/j.euroneuro.2009.11.001
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Drug dependence is a chronic brain disease characterized by recurrent episodes of relapse, even when the person is motivated to quit. Relapse is a major problem and new pharmacotherapies are needed to prevent relapse episodes. The nicotinic acetylcholine receptor (nAChR) plays an important rote in nicotine dependence, alcohol consumption and cue-induced cocaine craving. Stimulation of the nAChR has been found to alter and modulate cell firing in brain areas important for the maintenance of drug dependence. Varenicline, an alpha 4 beta 2 nAChR partial agonist and an alpha 7 nAChR full agonist registered for the treatment of nicotine dependence, significantly reduces nicotine craving and prevents relapse. In addition, varenicline reduces alcohol consumption in rats. Based on a review of the available literature, we hypothesize a potential rote for varenicline in the prevention of relapse in patients recovering from drug dependence other than nicotine dependence. (C) 2009 Elsevier B.V. and ECNP. All rights reserved.
引用
收藏
页码：69 / 79
页数：11
相关论文
共 50 条
  • [31] APN1125: A clinical stage α7 nicotinic acetylcholine receptor partial agonist
    Koelsch, Gerald
    Detke, Michael J.
    Stevens, Karen E.
    Meltzer, Leonard T.
    Terry, Alvin V., Jr.
    Callahan, Patrick M.
    Yoshimura, Ryan F.
    Bilcer, Geoffrey
    Anderson, Paul C.
    Ng, John
    Ng, Raymond
    Kelly, Terence A.
    BIOCHEMICAL PHARMACOLOGY, 2015, 97 (04) : 636 - 636
  • [32] Molecular dissection of tropisetron, an α7 nicotinic acetylcholine receptor-selective partial agonist
    Papke, RL
    Schiff, HC
    Jack, BA
    Horenstein, NA
    NEUROSCIENCE LETTERS, 2005, 378 (03) : 140 - 144
  • [33] Is the voltage-dependence of nicotinic acetylcholine receptor channel gating independent of the agonist charge?
    Tascione, RA
    Auerbach, A
    BIOPHYSICAL JOURNAL, 1999, 76 (01) : A373 - A373
  • [34] Differential generalization among nicotinic acetylcholine receptor agonists in nicotine, varenicline, and epibatidine drug discriminations in mice
    Moura, Fernando
    McMahon, Lance
    FASEB JOURNAL, 2014, 28 (01):
  • [35] Treatment for Tobacco Dependence: Effect on Brain Nicotinic Acetylcholine Receptor Density
    Brody, Arthur L.
    Mukhin, Alexey G.
    Shulenberger, Stephanie
    Mamoun, Michael S.
    Kozman, Maggie
    Phuong, Jonathan
    Neary, Meaghan
    Trinh Luu
    Mandelkern, Mark A.
    NEUROPSYCHOPHARMACOLOGY, 2013, 38 (08) : 1548 - 1556
  • [36] Treatment for Tobacco Dependence: Effect on Brain Nicotinic Acetylcholine Receptor Density
    Arthur L Brody
    Alexey G Mukhin
    Michael S Stephanie Shulenberger
    Maggie Mamoun
    Jonathan Kozman
    Meaghan Phuong
    Trinh Neary
    Mark A Luu
    Neuropsychopharmacology, 2013, 38 : 1548 - 1556
  • [37] Pre-clinical properties of the α4β2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence
    Rollema, H.
    Shrikhande, A.
    Ward, K. M.
    Tingley, F. D., III
    Coe, J. W.
    O'Neill, B. T.
    Tseng, E.
    Wang, E. Q.
    Mather, R. J.
    Hurst, R. S.
    Williams, K. E.
    de Vries, M.
    Cremers, T.
    Bertrand, S.
    Bertrand, D.
    BRITISH JOURNAL OF PHARMACOLOGY, 2010, 160 (02) : 334 - 345
  • [38] Improved and 'Nitrosamines Free' Process for the Preparation of an α4β2 Neuronal Nicotinic Acetylcholine Receptor Agonist-Varenicline Tartrate
    Goura, Ramesh
    Katari, Naresh Kumar
    Ramprasad, A. K.
    Rebelli, Pradeep
    Babu, Manabolu Surya Surendra
    POLYCYCLIC AROMATIC COMPOUNDS, 2023, 43 (06) : 5299 - 5309
  • [39] Efficacy of varenicline, an α4β2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation -: A randomized controlled trial
    Jorenby, Douglas E.
    Hays, J. Taylor
    Rigotti, Nancy A.
    Azoulay, Salomon
    Watsky, Eric J.
    Williams, Kathryn E.
    Billing, Clare B.
    Gong, Jason
    Reeves, Karen R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2006, 296 (01): : 56 - 63
  • [40] A randomized, placebo-controlled trial of varenicline, a selective α4β2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers
    Tsai, Shih-Tzu
    Cho, Hong-Jun
    Cheng, Huey-Shinn
    Kim, Cheol-Hwan
    Hsueh, Kuang-Chieh
    Billing, Clare B., Jr.
    Williams, Kathryn E.
    CLINICAL THERAPEUTICS, 2007, 29 (06) : 1027 - 1039
12345